Shasqi

Shasqi is developing a next-generation drug delivery platform based on click chemistry, a Nobel Prize-winning technology, to precisely target cancer therapies. Its CAPAC® platform employs a two-step, pre-targeting approach: first, a 'clickable binder' localizes to the tumor, then a systemically administered 'clickable payload' (chemotherapy or radioisotope) is activated only upon clicking with the binder at the tumor. This modular system is designed to improve the therapeutic index of cancer drugs beyond current standards like Antibody-Drug Conjugates (ADCs). The company has validated its platform in the clinic and is advancing a pipeline of novel therapies for cancers with limited treatment options.

CAPAC® (Click Activated Protodrugs Against Cancer) platform, a pre-targeting approach using in-vivo bioorthogonal click chemistry to activate therapeutic payloads (chemotherapy or radioisotopes) specifically at the tumor site.

Shasqi competes in the targeted oncology therapy space, primarily against developers of Antibody-Drug Conjugates (ADCs) like AstraZeneca, Daiichi Sankyo, and Gilead, and targeted radiopharmaceutical companies like Novartis and Point Biopharma. Its key differentiator is the use of exogenous click chemistry for activation, which is distinct from the biological linker-payload systems used in ADCs. Competitors are also exploring alternative pre-targeting methods and novel conjugation chemistries.